AOD-9604 5mg

1. 1

   Remove the 5 mg AOD-9604 vial from −20 °C storage and allow it to equilibrate to room temperature for 10–15 minutes.

2. 2

   Disinfect the rubber stoppers of both the peptide vial and the bacteriostatic water vial using sterile alcohol swabs.

3. 3

   Draw exactly 2.0 mL of bacteriostatic water into a sterile syringe.

4. 4

   Insert the needle into the peptide vial at a 45-degree angle, allowing the diluent to run slowly down the inner glass wall to minimize agitation.

5. 5

   Gently swirl and roll the vial between your palms until the lyophilisate is completely dissolved and clear; avoid shaking.

6. 6

   Label the vial with the reconstitution date and working concentration (2.5 mg/mL), then immediately store at 2–8 °C.

Overview

AOD-9604 is a modified synthetic peptide derived from the carboxyl-terminal region of human growth hormone, specifically residues 177 through 191 with an added tyrosine residue for molecular stability. Developed originally in the late 1990s as a targeted anti-obesity agent, the peptide was designed to isolate the lipolytic and anti-lipogenic properties of natural growth hormone while avoiding its systemic endocrine consequences. Unlike full-length growth hormone, AOD-9604 does not stimulate insulin-like growth factor 1 production, nor does it adversely interfere with systemic glucose metabolism or induce peripheral insulin resistance. At the molecular level, preclinical studies demonstrate that AOD-9604 enhances lipolysis and suppresses de novo lipogenesis in isolated adipocytes through receptor-independent pathways, modulating enzymatic breakdown of intracellular triglycerides without activating classic growth hormone receptors. In animal models of diet-induced and genetic obesity, administration of the peptide produced consistent reductions in adipose pad mass and increased fatty acid oxidation without altering lean muscle tissue or linear growth markers. Clinical evaluation advanced through human Phase IIb trials to explore oral and subcutaneous regimens for weight reduction. Although the peptide established a favorable safety profile and demonstrated acceptable tolerability without generating neutralizing antibodies, clinical development was discontinued due to inconsistent human weight-loss efficacy compared to preclinical endpoints. Today, AOD-9604 remains an active reference compound in academic and laboratory research focused on adipocyte lipid kinetics, signaling pathways, and comparative metabolic studies.

1. 1.Heffernan M et al., Endocrinology, 2001 — Effects of hGH and its lipolytic fragment AOD9604 on lipid metabolism and weight loss in obese rodent models
2. 2.Ng FM et al., Journal of Endocrinology, 2000 — Metabolic actions of synthetic C-terminal human growth hormone fragment (AOD9604) without altering insulin sensitivity
3. 3.Stier H et al., Journal of Endocrinology and Metabolism, 2013 — Safety, tolerability, and metabolic profile of AOD9604 in clinical evaluation
4. 4.Moré MI and Kenley D, Journal of Endocrinology and Metabolism, 2014 — Safety and metabolism of AOD9604 as a novel nutraceutical compound

Peptide VialView

Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.